Safety of HRX215 in Patients After Minor and Major Liver Resection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-06

Study Completion Date

2026-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if HRX215 is safe and tolerable in adults who have undergone surgical removal of metastatic tumor(s) due to colorectal carcinoma in the liver.

The main question it aims to answer are:

1. to learn about the safety of HRX215
2. to learn about how the body absorbs, distributes, and gets rid of HRX215 . Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to see what medical problems participants have when taking HRX215.

Participants will:

Take HRX215 or a placebo twice a day for 28 days Daily visits for 7 days for checkups and tests which may either be in the hospital or outpatient after 3 days. Clinic visits every two weeks for the next two visits. The visit at two weeks may be a home visit or clinic visit. Additional clinic visits 3 months and 6 months after the start of treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sorafenib for Residue Disease After Resection With Curative Intent

NCT01751763

Carcinoma, Hepatocellular

COMPLETED

Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma

NCT00077389

Liver Cancer

UNKNOWN PHASE2

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

NCT05194293

Stage IB Hepatocellular Carcinoma AJCC v8 Stage II Hepatocellular Carcinoma AJCC v8 Stage III Hepatocellular Carcinoma AJCC v8 +1 more

ACTIVE_NOT_RECRUITING PHASE2

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

NCT00692770

Carcinoma, Hepatocellular

COMPLETED PHASE3

Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery

NCT01182272

Liver Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is designed to evaluate primarily the safety of HRX215, first after minor liver resection and, when safety is established, in those patients after major liver resection. Participants will start treatment within 1-3 days after liver resection and will receive 28 day treatment with HRX215 twice daily or placebo with follow up visits 3 and 6 months after completion of treatment.

The pharmacokinetics will be compared with the results of the phase I studies, whereas efficacy will be evaluated only descriptively. Secondary objectives will include evaluation of differences in liver volume recovery postoperatively and clinical outcomes including days in the ICU and 90 day mortality in participants who receive treatment with HRX215 vs. placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Liver Metastases Liver Resection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active treatment minor hepatic resection

5 participants will receive HRX215 250 mg twice daily orally within 1-3 days after minor (\<=31%) liver resection for colorectal liver metastases for 28 days.

Group Type EXPERIMENTAL

HRX215 capsules

Intervention Type DRUG

HRX215 capsules 250 mg orally twice daily

Active treatment arm major hepatic resection

10 participants will receive HRX215 250 mg twice daily orally within 1-3 days after major (50-72%) liver resection for colorectal liver metastases for 28 days.

Group Type ACTIVE_COMPARATOR

HRX215 capsules

Intervention Type DRUG

HRX215 capsules 250 mg orally twice daily

placebo arm major hepatic resection

10 participants will receive placebo capsules with matching appearance to HRX215 twice daily orally within 1-3 days after major (50-72%) liver resection for colorectal liver metastases for 28 days

Group Type PLACEBO_COMPARATOR

Placebo capsules

Intervention Type DRUG

placebo capsules matching appearance of HRX215

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HRX215 capsules

HRX215 capsules 250 mg orally twice daily

Intervention Type DRUG

Placebo capsules

placebo capsules matching appearance of HRX215

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Stable male and female patients between 18 and 75 years within 1-3 days after extended resection of the right or left liver lobe due to metastases of a colon carcinoma, but otherwise normal liver parenchyma proven by histopathology assessment of a liver biopsy within 3 months before surgery and liver functional parameters.
2. For the pilot phase less extended resections (remnant liver volume \&gt;69%) are required)
3. Percentage of Remnant Liver Volume (RLV) 28%-50% (randomized part of the study)

\-

Exclusion Criteria

1. Liver Cirrhosis
2. Preoperative presence of clinical ascites
3. Any other liver cancer
4. BMI \>35 kg/m2
5. ASA Score\>4
6. CC Score \>0: all patients with pre-operatively or intra-operatively diagnosed peritoneal carcinosis or other pre-op or intra-op findings which would deem the patient to be unresectable, are excluded.
7. Incomplete liver metastasis resection -

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No